Log in

Mylan Stock Forecast, Price & News

+0.17 (+1.18 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $14.54
50-Day Range
MA: $15.23
52-Week Range
Now: $14.54
Volume9.14 million shs
Average Volume6.18 million shs
Market Capitalization$7.52 billion
P/E Ratio27.43
Dividend YieldN/A
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Read More
Mylan logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MYL



Sales & Book Value

Annual Sales$11.50 billion
Cash Flow$7.86 per share
Book Value$23.02 per share


Net Income$16.80 million


Market Cap$7.52 billion
Next Earnings Date11/3/2020 (Estimated)
+0.17 (+1.18 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Mylan (NASDAQ:MYL) Frequently Asked Questions

How has Mylan's stock price been impacted by COVID-19?

Mylan's stock was trading at $14.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MYL shares have increased by 0.5% and is now trading at $14.54.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Mylan?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Mylan

When is Mylan's next earnings date?

Mylan is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Mylan

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) released its quarterly earnings data on Thursday, August, 6th. The company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.16. The firm had revenue of $2.73 billion for the quarter, compared to analysts' expectations of $2.74 billion. Mylan had a return on equity of 20.43% and a net margin of 2.35%. The business's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.03 earnings per share.
View Mylan's earnings history

What guidance has Mylan issued on next quarter's earnings?

Mylan updated its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.5-12 billion, compared to the consensus revenue estimate of $11.62 billion.

What price target have analysts set for MYL?

9 analysts have issued twelve-month target prices for Mylan's stock. Their forecasts range from $16.00 to $27.00. On average, they expect Mylan's stock price to reach $20.33 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price.
View analysts' price targets for Mylan

Who are some of Mylan's key competitors?

What other stocks do shareholders of Mylan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Intel (INTC), NVIDIA (NVDA), Cisco Systems (CSCO), Starbucks (SBUX) and General Electric (GE).

Who are Mylan's key executives?

Mylan's management team includes the following people:
  • Mr. Robert J. Coury, Exec. Chairman (Age 59, Pay $1.83M)
  • Ms. Heather Bresch, CEO & Exec. Director (Age 51, Pay $5.64M)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 59, Pay $4.47M)
  • Mr. Anthony Mauro, Chief Commercial Officer (Age 47, Pay $2.55M)
  • Mr. Paul B. Campbell, Chief Accounting Officer, Sr. VP & Corp. Controller

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Who are Mylan's major shareholders?

Mylan's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pzena Investment Management LLC (3.32%), Retirement Systems of Alabama (0.24%), BNP Paribas Arbitrage SA (0.15%), Harel Insurance Investments & Financial Services Ltd. (0.11%), LSV Asset Management (0.11%) and DekaBank Deutsche Girozentrale (0.10%). Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt.
View institutional ownership trends for Mylan

Which institutional investors are selling Mylan stock?

MYL stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., KBC Group NV, State of Alaska Department of Revenue, Standard Life Aberdeen plc, State of New Jersey Common Pension Fund D, Toronto Dominion Bank, Nisa Investment Advisors LLC, and Robeco Institutional Asset Management B.V..
View insider buying and selling activity for Mylan

Which institutional investors are buying Mylan stock?

MYL stock was acquired by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, DekaBank Deutsche Girozentrale, BNP Paribas Arbitrage SA, Alaska Permanent Fund Corp, Polianta Ltd, LSV Asset Management, Banque Cantonale Vaudoise, and State of Michigan Retirement System. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury, and Sjoerd S Vollebregt.
View insider buying and selling activity for Mylan

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $14.54.

How big of a company is Mylan?

Mylan has a market capitalization of $7.52 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

What is Mylan's official website?

The official website for Mylan is www.mylan.com.

How can I contact Mylan?

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.